Oppenheimer Acted as Co-Lead Manager for Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, for which Kura has initiated a registration-directed trial in recurrent or metastatic patients with HRAS mutant HNSCC. In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, which has been cleared to begin a Phase 1 clinical trial.
For more information please contact:
Healthcare Investment Banking Equity Capital Markets
Michael A. Margolis, R.Ph. Peter Bennett
Co-Head of Healthcare Investment Banking Head of Equity Capital Markets
212-667-7622 212-667-6285
MichaelA.Margolis@opco.com Peter.Bennett@opco.com
Stefan Loren, Ph.D.
Managing Director
858.202.3880
Stefan.Loren@opco.com
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer and Oppenheimer Asset Management Inc (OAM) are principle subsidiaries of Oppenheimer Holdings Inc., and provide a full range of wealth management, securities brokerage, capital markets, and investment banking services to high-net worth individuals, families, corporate executives, businesses and institutions. The Firm creates integrated financial strategies tailored to each client’s goals. For over 130 years of operation, Oppenheimer has emphasized customer service, integrity and intellectual objectivity.
2019 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 2643974.1